Case-control study reveals CXCL16 links with bone resorption in total hip arthroplasty, suggesting a new therapeutic target.
Our findings reveal a significant association between elevated CXCL16 expression and an increased RANKL/OPG ratio in periprosthetic synovial tissues, suggesting a role for CXCL16 in promoting osteoclast differentiation and activity. These findings offer preliminary insights into CXCL16 as a biomarker and a potential therapeutic target for managing bone resorption in aseptic loosening.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: